Buradasınız

BÖBREK NAKLÎ YAPILAN HASTALARDA SÎKLOSPORÎN A KULLANIMININ MEME HASTALIĞI GELİŞME RİSKİNE ETKİSİ

THE RISK OF BREAST DISEASE IN RENAL TRANSPLANT PATIENTS RECEIVING CYCLOSPORIN A

Journal Name:

Publication Year:

Keywords (Original Language):

Abstract (2. Language): 
The risk of breast lesion development in patients under immunosupressive therapy is controversial. The aim of this study was to assess the risk of breast disease in female renal transplant recipients Twenty-two female renal transplant recipients with a functioning graft are included in the study. Physical examination, breast ultrasound and mammography in patients over 35 years were done. The levels of serum measured, progesteron and prolactin were estimated. In all of the patients, triple immunosupressive therapy consisted of cyclosporin (CsA), steroids and mycophenolate mofetil or azathioprine was given, ATG was used for induction in cadaveric renal transplantation. The mean age of the patients was 30,8+11,4 years (range: 15-60). Mean follow-up time was 66,8+49,5 months (range: 12-199). In six patients (27,3%) benign breast lesions were found. Prolactin level was high in six patients. There was no correlation between hormon levels and breast lesions. Carcinoma was not found in any patient. The incidence of benign or malignant breast disease in our patients was found to be lower when compared with normal population. The number of patients was not enough to make any significant comparison between hormon levels and CsA and the breast lesions. Larger series of patients need to demostrate the effect of CsA therapy over breast diseases.
Abstract (Original Language): 
İmmunsupresif tedavi gören hastalarda memede lezyon gelişme riski tam olarak bilinmemektedir. Bu çalışmanın amacı böbrek nakli yapılan kadınlarda meme hastalığı riskini araştırmaktır. Böbrek nakli yapılan ve grefti çalışır durumda olan 22 kadına meme muayenesi, meme ultrasonografisi ve 35 yaş üstü hastalara ek olarak mammografi yapıldı. Serum estradiol, progestron ve prolaktin düzeyleri ölçüldü. İmmunsupresif tedavi protokolü canlı nakillerde steroid, siklosporin A (CsA), mikofenolat mofetil veya azatiopürinden oluşmaktaydı; kadavra nakillerde ek olarak indüksiyonda ATG kullanılmıştı. Hastaların ortalama takip süresi 66.8+ 49.5 ay (aralık: 12-199 ay), yaşı 30.8 ± 11.4 yaş (aralık: 15 -60yaş) idi. altı hastada (% 27.3) benign meme lezyonu tespit edildi Prolaktin kan düzeyi altı hastada yüksek bulundu. Meme patolojisi ile hormon düzeyleri arasında ilişki saptanmadı. Hiçbir hastada meme kanseri tespit edilmedi. Literatürle karşılaştırıldığında böbrek nakli yapılan hastalarımızda normal popülasyona göre benign ve malign meme patolojisi insidansı daha düşük bulunmuştur. Hasta sayısı az olduğundan hormonlarla meme hastalıkları ve CsA kullanımı arasında istatistiksel olarak anlamlı bir ilişki kurulamamıştır. CsA kullanımının meme hastalıkları üzerine etkisini belirleyebilmek için daha geniş hasta popülasyonlarında daha ileri karşılaştırmalı çalışmalar gerekmektedir.
FULL TEXT (PDF): 
93-95

REFERENCES

References: 

1. Stewart
T
, Tsai SC, Grayson H, Henderson R, Opelz G. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 1995;346(suppl 8978):796-798.
2.
Cervell
i V, Orlando G, Giudicearidrea F, et al. Gigantomastia and breast lumps in a kidney transplant
recipient. Transplant Proc 1999;31:3224-3225.
3. Baildam AD, Higgins RM, Hurley E, et al. Cyclosporin A and multiple fibroadenomas of the breast. Br J Surg
1996;83(suppl 12): 1755-1757.
4. Muttarak M, Peh WC, Chaiwun B, Lumlertgul D.
Multiple bilateral giant fibroadenomas associated with cyclosporine A therapy in a renal transplant recipient. Australas Radiol 2001;45(suppI 4):517-519.
5. Campbell A, Moazami N, Ditkoff BA, Kurtz E, Estabrook A, Schnalbel F. Short-term outcome of chronic immunosuppression on the development of breast lesions in premenopausal heart and lung transplant
patients. J Surg Res 1998;78(suppl l):27-30.
6. N'zi K, Asquier E, Fauchier F, et al. Does renal transplantation increase the risk of breast diseases? J
Radiol 2001;82(suppl 4):469- 472.
7. Bernard DJ, Maurizis JC, Sauvezie B, et al. Antagonism of prolactin binding by cyclosporine A on MCF7 breast tumor cell line. Anticancer Res 1991;ll(suppl 6):2147-2151.
8. Favy DA, Rio PG, Vissac C, Maurizis JC, Bignon YJ,
Bernard-Gallon DJ. Cyclosporine A inhibition of prolactin-dependent up-regulation of BRCA1 protein expression in human breast cell lines. Anticancer Res
2000;20(suppl 3A): 1703-1704.
9. Kleer CG, Tseng MD, Gutsch DE, et al. Detection of
Epstein-Barr virus in rapidly growing fibroadenomas of the breast in immunosuppressed hosts. Mod Pathol
2002;15(suppl7):759-764.
95

Thank you for copying data from http://www.arastirmax.com